Assessment of Host-targeted Nanobody Therapeutics
ID: HT942626QE003Type: Sources Sought
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYFORT DETRICK, MD, 21702, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

PSC

GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH (AJ11)

Set Aside

No Set aside used (NONE)

Original Source

https://sam.gov/workspace/contract/opp/37a309976cd744b89e169bddc7ba06fb/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency (DHA), is seeking contractors for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract focused on the assessment of host-targeted nanobody therapeutics. The primary objective is to evaluate and refine nanobody therapies using established in vitro porcine blood-brain barrier (BBB) models, develop novel BBB models, and address the challenges of delivering therapeutic payloads into the Central Nervous System (CNS) for neurotropic viral infections. This initiative is critical for advancing therapeutic options against high-priority pathogens, as it aims to overcome the limitations posed by the blood-brain barrier. Interested contractors can contact Grant A. Gratton at grant.a.gratton.civ@health.mil or Emily K. O'Hara at emily.k.ohara.civ@health.mil for further details, with the contract having a five-year ordering period and performance monitored through a Quality Assurance Surveillance Plan (QASP).

    Files
    Title
    Posted
    A02-SOO 12-31-2025.docx
    The U.S. Army Medical Research of Infectious Diseases (USAMRIID) and Defense Health Agency (DHA) are seeking a contractor to evaluate host-targeted nanobody therapeutics. This Indefinite Delivery/Indefinite Quantity (IDIQ) contract will involve assessing nanobody therapies using established in vitro porcine blood-brain barrier (BBB) models and developing novel in vitro BBB models. The primary goal is to address challenges in trafficking molecules into the Central Nervous System (CNS) for therapeutic payload delivery, particularly for neurotropic viral infections. The contractor will refine existing BBB models, establish baseline transmigration efficiencies for nanobody therapies, assess targeted nanobody transmigration, and establish a non-human primate (NHP) BBB model. They will also provide subject-matter expertise to USAMRIID. The IDIQ contract has a five-year ordering period, with administrative tasks including study protocols, schedules, and various reports. The government will utilize a Quality Assurance Surveillance Plan (QASP) to monitor performance. Contractors are encouraged to use the Defense Technical Information Center (DTIC) for research.
    Lifecycle
    Title
    Type
    Assessment of Host-targeted Nanobody Therapeutics
    Currently viewing
    Sources Sought
    Similar Opportunities
    Traumatic Brain Injury Center of Excellence Warfighter Brain Health Research and Translation Support Services
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting proposals for the Traumatic Brain Injury Center of Excellence (TBICoE) Warfighter Brain Health Research and Translation Support Services under Solicitation Number HT001426RE001. The contractor will be responsible for providing personnel, equipment, and expertise to support TBICoE's mission of advancing research and clinical standards related to traumatic brain injuries (TBI) for military personnel and veterans. This initiative is crucial for addressing the increasing prevalence of TBI within the military, particularly in light of recent combat experiences and training-related exposures. Interested parties should direct inquiries to John A. Cowgill at john.a.cowgill4.ctr@health.mil or Sou J. Walls at sou.j.walls.civ@health.mil, with proposals due by December 30, 2025, and a contract value structured as Cost Plus Fixed Fee with four optional extension periods.
    DRAFT: OB BP IDIQ
    Dept Of Defense
    The Defense Threat Reduction Agency (DTRA) is seeking qualified contractors for the DRAFT: OB BP IDIQ opportunity, aimed at enhancing the capacity of partner nations to counter weapons of mass destruction (WMD) and chemical, biological, radiological, and nuclear (CBRN) threats. The contract will primarily support DTRA's Countering-WMD Security Cooperation Engagement Program (CSCEP) and the International Counterproliferation Program (ICP), focusing on establishing or enhancing partner nation capabilities to deter, detect, interdict, or respond to WMD proliferation. This initiative is critical for the Department of Defense and U.S. Government in their efforts to deter strategic attacks and prevail against WMD-armed adversaries. Interested parties can reach out to primary contact Jocelyn Fritz at jocelyn.m.fritz.civ@mail.mil or 571-616-5277, or secondary contact Eric Rode at eric.m.rode.civ@mail.mil or 571-616-6145 for further information. The final Request for Proposal (RFP) is expected to be issued before the end of the fiscal year, with updates available on the SAM.gov entry.
    BATTLEFIELD WOUND INFECTION PREVENTION AND TREATMENT (BWI P&T): BARRIER COMBINATION PRODUCT DEVELOPMENT
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is conducting market research for the development of a barrier combination product aimed at preventing and treating battlefield wounds and subsequent infections. This initiative, part of the Battlefield Wound Infection Prevention and Treatment (BWI P&T) program, seeks to identify commercial solutions that can effectively address the unique challenges of wound care in austere environments, where medical resources may be limited. The barrier combination product is expected to play a crucial role in a Family of Systems (FoS) approach, providing innovative solutions for both military and commercial applications in wound care. Interested parties are invited to submit their responses by January 20, 2026, at 2:00 PM Eastern, via email to the primary contacts, Jeanette Collins and Julie Burns, whose emails are provided in the opportunity overview. This RFI is for planning purposes only, and no contract will be awarded based on the responses received.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking proposals for extramural biomedical research and development. This opportunity is issued by the DEFENSE HEALTH AGENCY (DHA) under the BROAD AGENCY ANNOUNCEMENT (BAA) HT9425-23-S-SOC1. The purpose of this BAA is to solicit research and development ideas to advance the state-of-the-art or increase knowledge in the field. The projects funded under this BAA should focus on basic and applied research rather than the development of specific systems or hardware solutions. The research and development funding is expected to benefit both military and civilian medical practice and knowledge. Interested parties must submit a pre-proposal through the electronic Biomedical Research Application Portal (eBRAP). If selected, the offeror will be invited to submit a full proposal or application through Grants.gov. The BAA is open for a 5-year period, from August 1, 2023, to July 31, 2028. The BAA with revised research areas of interest and General Submission Instructions can be found on Grants.gov using opportunity number HT9425-23-S-SOC1.
    NAWCWD Broad Agency Announcement
    Dept Of Defense
    The Department of Defense, through the Naval Air Warfare Center Weapons Division (NAWCWD), has issued a Broad Agency Announcement (BAA) for research and development in biotechnology, specifically excluding nanobiotechnology. This opportunity invites proposals for innovative solutions that align with the objectives outlined in the Federal Acquisition Regulation and the Department of Defense Grants and Agreements Regulations, emphasizing the importance of advancing national defense capabilities. NAWCWD reserves the right to select for award all, some, or none of the proposals submitted, and it is important to note that no funding will be provided for proposal development costs. Interested parties can reach out to Kyle Hedman at kyle.d.hedman.civ@us.navy.mil or by phone at 760-793-3166 for further inquiries regarding this announcement.
    Customer Care Prototyping - Commercial Solution Opening (Notice of Availability)
    Dept Of Defense
    The Defense Health Agency (DHA) is seeking innovative solutions through its "Customer Care Prototyping 2025-2026" initiative, aimed at enhancing customer care within the Military Health System (MHS). This opportunity invites prototype projects under the authority of 10 U.S.C. § 4022, focusing on developing a foundational platform that prioritizes agile development, self-service support, and data-driven insights to improve mission effectiveness and customer sentiment while reducing costs. Interested vendors should monitor SAM for updates regarding submission instructions and evaluation criteria, with the first "Season Notice" expected in Q1 FY26. For inquiries, contact Gabriela Hurte at gabriela.y.hurte.civ@health.mil or Sonya Edom at sonya.m.edom.civ@health.mil.
    BROAD AGENCY ANNOUNCEMENT (BAA) RESEARCH AND DEVELOPMENT IN SUPPORT OF THE JOINT PROGRAM EXECUTIVE OFFICE FOR CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR DEFENSE (JPEO-CBRND), JPM MEDICAL AND JPL EB
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is seeking research and development services in support of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB. The service being procured is for the identification of the best available science in the areas of research interest, including novel solutions and improved methods for developing medical countermeasures. The government is specifically interested in enabling technologies, life cycle bioinformatics, and improved logistics tracking. The procurement notice is available on SAM.gov and the JPEO-CBD website. Potential offerors are encouraged to communicate with the JPMO technical contacts for proposal ideas. For any questions or inquiries, contact usarmy.detrick.mcs.mbx.baa@mail.mil.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1
    Dept Of Defense
    The Department of Defense, through the United States Special Operations Command (USSOCOM), is soliciting proposals for the Broad Agency Announcement (BAA) focused on Extramural Biomedical and Human Performance Research and Development, which will be open from August 1, 2023, to July 31, 2028. This initiative aims to enhance military medical capabilities by funding innovative research addressing critical areas such as trauma care, brain health, casualty management, and human performance optimization, with individual project budgets ranging from $700,000 to $5 million. The research funded under this BAA is intended to benefit both military and civilian medical practices, emphasizing the importance of applicable solutions for unique operational environments. Interested organizations, including non-profits and educational institutions, must submit a pre-proposal via the electronic Biomedical Research Application Portal (eBRAP) before being invited to submit a full proposal through Grants.gov, with a total annual funding budget of $10 million available for selected projects. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or Jessee Chege at jessee.t.chege.civ@health.mil.
    IDIQ for Blood Bank Reagents for NMRTC Sigonella, Italy
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is seeking sources for an Indefinite Delivery Indefinite Quantity (IDIQ) contract for blood bank reagents to support the Navy Medicine Readiness and Training Command (NMRTC) in Sigonella, Italy. The procurement aims to ensure the availability of essential reagents for safe blood transfusions, which are critical for inpatient needs, naval ships, and the European Theatre blood depot. The selected supplier must comply with American Blood Bank Association, Navy Blood Program, and FDA standards, ensuring strict temperature-controlled shipments and on-demand deliveries within four days due to the short expiration dates of the reagents. Interested parties must submit their responses to the Request for Information (RFI) by January 14, 2026, at 5 PM EST, directed to Melissa Peregrino-White at melissa.peregrino-white.civ@health.mil.
    DTRA CWMD Security Cooperation Engagement Program IDIQ
    Dept Of Defense
    The Defense Threat Reduction Agency (DTRA) is seeking contractors for the Countering Weapons of Mass Destruction (CWMD) Security Cooperation Engagement Program (CSCEP) through an Indefinite Delivery Indefinite Quantity (IDIQ) contract. This program aims to enhance the capabilities of partner nations in responding to Chemical, Biological, Radiological, and Nuclear (CBRN) incidents, thereby improving global national security. The contractor will be responsible for training, equipping, and supporting partner nations, including logistics management and event planning, with a focus on compliance with U.S. and international regulations. Interested parties should note that the solicitation will be released in the second quarter of fiscal year 2025, and inquiries can be directed to Jocelyn Fritz or Eric M Rode at the provided email address.